Celcuity (CELC) Stock: Buy, Sell, or Hold?
CELC - Celcuity Inc. Common Stock
$65.78
-5.47 (-7.68%)
▼
5d:
-17.28%
30d:
-29.28%
90d:
-42.05%
WAIT
LOW Confidence
Analysis Updated: Oct 7, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When CELC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CELC is down 17.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CELC is down 17.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CELC is currently trading at $65.78, which is considered oversold relative to its 30-day fair value range of $75.17 to $90.54. From a valuation perspective, the stock is trading at a discount (Forward PE: -822.2) compared to its historical average (125.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CELC is in a downtrend. The price is currently testing key support at $64.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $156.91 (+138.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CELC is in a downtrend. The price is currently testing key support at $64.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $156.91 (+138.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$75.17 -
$90.54
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding CELC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (58/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.7%)
- BULLISH: Trading 138.5% below Wall St target ($156.91)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$75.17 -
$90.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$64.15
Resistance Level
$88.68
Current Trend
Downtrend
Technical data as of
Oct 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-822.25
Wall Street Target
$156.91
(+138.5%)
PE vs Historical
-822.3 vs 125.4
CHEAP
Share & Embed Analysis
Last updated: October 08, 2026 1:35 AM ET
Data refreshes hourly during market hours. Next update: 2:35 AM
Data refreshes hourly during market hours. Next update: 2:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CELC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$294 | 60 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
27 analysts |
$853 | 55 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
19 analysts |
$644 | 71 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 53 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 68 BUY |
Advanced CELC Option Strategies
Professional options setups generated by AI based on today's CELC price and gamma walls.
